Can lung volume reduction surgery improve survival in emphysema?

Who actually lives longer after lung volume reduction surgery?

The survival benefit of lung volume reduction surgery (LVRS) is not universal — it depends heavily on which type of emphysema you have and how well you can exercise. The strongest evidence comes from the NETT trial, which showed that patients with upper-lobe-predominant emphysema and low baseline exercise capacity had a dramatically lower risk of death over long-term follow-up compared to medical therapy alone (odds ratio 0.45, meaning roughly half the mortality risk) [11]. This is the group where LVRS clearly improves survival.

For patients outside this sweet spot, the picture is different. A 2025 network meta-analysis of 26 randomized controlled trials (4,418 patients) found that, overall, no lung volume reduction therapy — surgical or bronchoscopic — significantly reduced mortality compared to standard medical care [1]. The overall early mortality rate was low (1.6%), but LVRS had the highest rates among the interventions [1]. This means that for the average emphysema patient, LVRS does not extend life; it improves quality of life and lung function, but not survival.

The NETT also identified a high-risk group — patients with very poor lung function (FEV1 ≤20% predicted) and either very low diffusing capacity (DLCO ≤20%) or homogeneous emphysema on CT scan — who had significantly higher early mortality after LVRS [11]. However, a 2026 study of 143 patients (17 high-risk by NETT criteria) found that modern surgical care can achieve comparable survival and transplant-free outcomes in these high-risk patients as in standard-risk patients, suggesting that the contraindication may be softening with improved techniques [7].

How does LVRS compare to less invasive valve procedures for survival?

When patients are eligible for both LVRS and bronchoscopic lung volume reduction (BLVR) with endobronchial valves, the two approaches appear equivalent in survival over one year. The CELEB trial, a randomized controlled trial directly comparing LVRS (41 patients) to BLVR (47 patients) in patients suitable for both, found no difference in survival — one death occurred in each arm over 12 months [8]. Both treatments produced similar improvements in lung function, exercise capacity, and quality of life [8].

A 2022 propensity-matched study comparing 44 LVRS patients to 44 matched BLVR patients also found similar survival between groups over a median follow-up of 32 months [10]. However, LVRS led to better overall quality of life (86.4% of LVRS patients reported breathing improvement vs. 70.5% for BLVR) and required fewer re-interventions (20.5% vs. 52.3%), though it came with a longer hospital stay (median 10 vs. 6 days) [10].

A 2025 real-world study of a comprehensive lung volume reduction program (429 patients) found that transplant-free survival over 2.5 years was significantly better for patients who received endobronchial valves (hazard ratio 0.14, meaning 86% lower risk of death or transplant) compared to those who received usual care, while the survival benefit for LVRS was borderline significant (hazard ratio 0.7) [2]. This suggests that in routine practice, valve placement may offer a clearer survival advantage, possibly because it selects healthier patients.

If survival isn't guaranteed, what does LVRS actually deliver?

Even when LVRS doesn't extend life, it consistently and meaningfully improves how patients feel and function. The 2025 network meta-analysis found that LVRS significantly improved lung function (FEV1), reduced hyperinflation (residual volume), increased exercise capacity (6-minute walk distance), and improved quality of life compared to standard care — and it ranked as the most effective intervention among all lung volume reduction therapies [1]. These improvements are large enough to matter in daily life: a 2024 study of 67 LVRS patients reported a mean improvement of 10% in FEV1, a 49% reduction in residual volume, and a nearly 2-point drop on the dyspnea scale (mMRC) [6].

The price of these gains is higher complication rates. LVRS carries the highest risk of adverse events among all lung volume reduction therapies [1]. Prolonged air leak is the most common complication, occurring in 42% of bilateral LVRS patients in one study [3], and it often requires reoperation — a 2023 study found a 13% reoperation rate, with air leak being the indication in 84% of cases [5]. Reoperation itself increases 30-day mortality risk (odds ratio 5.52) [5]. Bilateral LVRS, while offering greater functional improvement than unilateral, also comes with longer hospital stays (8 vs. 5 days) and more air leaks [9].

Importantly, LVRS does not preclude future lung transplantation. A multicenter matched analysis of 615 patients found that prior LVRS did not impact short- or long-term survival after bilateral lung transplantation (1-year survival 92.3% vs. 91.3% for controls) [4]. This means LVRS can be a bridge to transplant, not a barrier.

About These Sources

This answer is built on 11 peer-reviewed studies — published from 2016 to 2026, 6 from 2024 or later, 2 in Q1 journals — selected as the most relevant from 15 studies that passed quality screening, drawn from 48 papers retrieved from a database of over 500 million.

Sources used in this answer

Related research questions